Liposomes and PEGylated liposomes as drug delivery system | ||||
| Journal of advanced Biomedical and Pharmaceutical Sciences | ||||
| Article 5, Volume 3, Issue 2, April 2020, Page 80-88 PDF (785.89 K) | ||||
| Document Type: Review Articles | ||||
| DOI: 10.21608/jabps.2020.22937.1068 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Marwa Mohamed  ; Eman Alaaeldin; Amal Hussein; Hatem A. Sarhan
| ||||
| Department of Pharmaceutics, Faculty of Pharmacy, Minia University, 61519 Minia, Egypt | ||||
| Abstract | ||||
| Generally, it has been thought that PEG-conjugated nanocarriers are non-immunogenic. However, many reports have revealed that unexpected immune responses occur with such PEG-conjugated nanocarriers. The Most important one is the rapid clearance of PEGylated nanocarriers upon repeated administration which is called accelerated blood clearance phenomenon involving the production of antibodies against nanocarrier components, which reduces the safety and effectiveness of the encapsulated therapeutic agent. Such immunogenicity of PEGylated nanocarriers is a potential concern in the evaluation and clinic use of PEGylated therapeutics. Accordingly, screening of the immunogenicity of nanocarriers-based therapeutics is a prerequisite before their adoption into clinical settings to disclose any possible interactions with immune system. This review gives an overview of PEGylated liposomes, immunogenicity of PEG, explanation of accelerated blood clearance (ABC) phenomenon, its mechanism, various factors affecting it and side effects of PEGylated liposomes. | ||||
| Keywords | ||||
| Accelerated blood clearance (ABC) phenomenon; anti-PEG IgM; PEGylated liposomes; polyethylene glycol (PEG); marginal zone (MZ) | ||||
|
Statistics Article View: 2,002 PDF Download: 1,784 |
||||
